Posts

Clinical Trials in Prostate Cancer Care:

Image
Current Opportunities in Southern California A Comprehensive Overview for IPCSG Members February 2026 Introduction Southern California continues to serve as a major hub for innovative prostate cancer clinical research, with numerous trials currently recruiting patients across the spectrum of disease stages—from newly diagnosed localized disease to advanced metastatic castration-resistant prostate cancer (mCRPC). This article provides a comprehensive overview of active clinical trials available to patients in our region, focusing on trials at major academic medical centers and cancer research institutions including UC San Diego (UCSD) Moores Cancer Center, UCLA Jonsson Comprehensive Cancer Center, USC Norris Comprehensive Cancer Center, City of Hope, and Scripps. For men with prostate cancer and their families, clinical trials represent both an opportunity to access cutting-edge therapies before they become widely available and a chance to contribute to medical knowledge that may b...
Post a Comment
Read more

Theranostics in Radiation Oncology: What Is It, and Why Is It Important?

Image
Theranostics in Radiation Oncology: What Is It, and Why Is It Important? | CancerNetwork Theranostics: The Bridge Between Nuclear Medicine and Radiation Oncology in Modern Cancer Care BLUF (Bottom Line Up Front): Theranostics represents a paradigm shift in precision cancer treatment by combining diagnostic imaging with targeted radiopharmaceutical therapy. While traditional radiation oncology focuses on external beam radiation therapy (EBRT), theranostics falls primarily under nuclear medicine's domain, creating new collaborative care requirements across California and nationwide. Patients receiving these treatments need integrated team oversight to track cumulative radiation exposure from multiple sources, ensure coordinated care between specialties, and optimize treatment sequencing. FDA-approved theranostic agents currently exist for prostate cancer (Pluvicto/lutetium-177-PSMA-617) and neuroendocrine tumors (Lutathera), with alpha-emitting agents like actinium-225 showing pro...
Post a Comment
Read more

Protecting Your Heart During Hormone Therapy:

Image
IMPACT-ADT: Mitigating Cardiovascular Risks in Prostate Cancer Care - YouTube New Research Offers Hope BLUF (Bottom Line Up Front) A groundbreaking clinical trial at City of Hope is testing whether intermittent fasting or GLP-1 medications (like Ozempic) can protect prostate cancer patients from the cardiovascular risks of androgen deprivation therapy (ADT). This American Heart Association-funded study addresses a critical gap: most heart attacks in ADT patients occur within the first six months of treatment—before significant metabolic changes appear—suggesting an urgent need for early protective interventions. [See Sidebar: "Understanding Your Personal Risk Balance" for detailed analysis of when cardiovascular risk may outweigh cancer risk in your specific situation] The Cardiovascular Risk of Hormone Therapy When you start ADT for prostate cancer, your oncologist focuses on controlling your cancer. But cardiovascular disease represents a significant concurrent risk th...
Post a Comment
Read more